Research progress on biomarkers for predicting the efficacy of neoadjuvant therapy for muscle-invasive bladder cancer
10.12483/j.issn.1009-8291.2026.05.014
- VernacularTitle:肌层浸润性膀胱癌新辅助治疗疗效预测生物标志物研究进展
- Author:
Yongyin LIANG
1
;
Xiaodong WEN
2
Author Information
1. The Fifth Clinical Medical College, Shanxi Medical University, Taiyuan 030000
2. Department of Urology, Shanxi Provincial People's Hospital, Taiyuan 030000, China
- Publication Type:Journal Article
- Keywords:
muscle-invasive bladder cancer;
neoadjuvant therapy;
prediction of treatment response;
molecular subtyping of bladder cancer;
biomarkers;
N-cadherin 2;
keratin 13;
phosphocholine cytidylyltransferase;
CXC chemokine ligand 13;
Escherichia coli immunoglobulin G;
heat shock protein family A Member 1A
- From:
Journal of Modern Urology
2026;31(5):475-480
- CountryChina
- Language:Chinese
-
Abstract:
In the era of bladder-preserving therapy (BPT) for muscle-invasive bladder cancer (MIBC), accurate prediction of the efficacy of neoadjuvant therapy (NAT) is of critical importance.This review focuses on novel strategies that go beyond traditional classification systems and identifies a series of innovative biomarkers derived from multi-omics research, such as Ncadherin 2, keratin 13, and phosphocholine cytidylyltransferase.These biomarkers can effectively bridge the functional information gap inherent in current molecular subtyping approaches.Through multi-dimensional integrated assessment, they offer a revolutionary prospect for achieving truly individualized NAT regimens.
